Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1

Bile salts and salts/metabolism LDL Liver cholesterol dyslipidemias

Journal

Journal of lipid research
ISSN: 1539-7262
Titre abrégé: J Lipid Res
Pays: United States
ID NLM: 0376606

Informations de publication

Date de publication:
13 Jul 2024
Historique:
received: 10 11 2023
revised: 05 06 2024
accepted: 27 06 2024
medline: 16 7 2024
pubmed: 16 7 2024
entrez: 15 7 2024
Statut: aheadofprint

Résumé

Bile salts can strongly influence energy metabolism through systemic signaling, which can be enhanced by inhibiting the hepatic bile salt transporter Na

Identifiants

DOI: 10.1016/j.jlr.2024.100594 PMID: 39009243
pubmed: 39009243
pii: S0022-2275(24)00099-3
doi: 10.1016/j.jlr.2024.100594
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100594

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declarations on interest none

Auteurs

Begoña Porteiro (B)

Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 69-71, Amsterdam, The Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam University Medical Center, Amsterdam, The Netherlands; CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain.

Reinout L P Roscam Abbing (RLP)

Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 69-71, Amsterdam, The Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam University Medical Center, Amsterdam, The Netherlands.

Wietse In Het Panhuis (W)

Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 69-71, Amsterdam, The Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam University Medical Center, Amsterdam, The Netherlands.

Dirk R de Waart (DR)

Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 69-71, Amsterdam, The Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam University Medical Center, Amsterdam, The Netherlands.

Suzanne Duijst (S)

Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 69-71, Amsterdam, The Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam University Medical Center, Amsterdam, The Netherlands.

Isabelle Bolt (I)

Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 69-71, Amsterdam, The Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam University Medical Center, Amsterdam, The Netherlands.

Esther W Vogels (EW)

Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 69-71, Amsterdam, The Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam University Medical Center, Amsterdam, The Netherlands.

Johannes H M Levels (JHM)

Amsterdam UMC, University of Amsterdam, Department of Experimental Vascular Medicine, Meibergdreef 9, Amsterdam, the Netherlands.

Laura A Bosmans (LA)

Amsterdam UMC, location AMC, University of Amsterdam, Department of Medical Biochemistry, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Immunity and Infection, Amsterdam, the Netherlands.

Winnie G Vos (WG)

Amsterdam UMC, location AMC, University of Amsterdam, Department of Medical Biochemistry, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Immunity and Infection, Amsterdam, the Netherlands.

Ronald P J Oude Elferink (RPJ)

Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 69-71, Amsterdam, The Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.

Esther Lutgens (E)

Amsterdam UMC, location AMC, University of Amsterdam, Department of Medical Biochemistry, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Immunity and Infection, Amsterdam, the Netherlands; Department of Cardiovascular Medicine and Immunology, Mayo Clinic, Rochester, Minnesota, USA.

Stan F J van de Graaf (SFJ)

Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 69-71, Amsterdam, The Netherlands; Amsterdam Gastroenterology, Endocrinology and Metabolism (AGEM), Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: k.f.vandegraaf@amsterdamumc.nl.

Classifications MeSH